Citius Oncology, Inc. Net Income
Citius Oncology, Inc. (CTOR) reported Net Income of -$8.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-14
- Citius Oncology, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$8.92M.
- Citius Oncology, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$26.61M.
- Citius Oncology, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$5.53M.
- Citius Oncology, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$5.00M.
- Citius Oncology, Inc. net income (loss) attributable to parent for fiscal 2025 was -$24.76M.
- Citius Oncology, Inc. net income (loss) attributable to parent for fiscal 2024 was -$21.15M.
- Citius Oncology, Inc. net income (loss) attributable to parent for fiscal 2023 was $2.42M.
- Citius Oncology, Inc. net income (loss) attributable to parent for fiscal 2023 was -$12.70M.
| Period end | Net Income (Loss) Attributable to Parent 1 month | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 7 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 10 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.92M 10-Q · filed 2026-08-14 | -$35.53M derived: sum of 2 quarters · filed 2026-08-14 | -$41.07M 10-Q · filed 2026-08-14 | -$46.06M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$26.61M 10-Q · filed 2026-08-14 | -$32.14M 10-Q · filed 2026-05-15 | -$37.14M derived: sum of 3 quarters · filed 2026-08-14 | -$42.51M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$5.53M 10-Q · filed 2026-08-14 | -$10.53M derived: sum of 2 quarters · filed 2026-08-14 | -$15.90M derived: sum of 3 quarters · filed 2026-08-14 | -$23.64M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-09-30 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$10.37M derived: sum of 2 quarters · filed 2026-08-14 | -$18.10M derived: sum of 3 quarters · filed 2026-08-14 | -$24.76M 10-K · filed 2025-12-23 | ||||
| 2025-06-30 | -$5.37M 10-Q · filed 2026-08-14 | -$13.11M derived: sum of 2 quarters · filed 2026-08-14 | -$19.76M 10-Q · filed 2026-08-14 | -$26.58M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$7.74M 10-Q · filed 2026-08-14 | -$14.39M 10-Q · filed 2026-05-15 | -$21.21M derived: sum of 3 quarters · filed 2026-08-14 | -$25.98M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2024-12-31 | -$6.66M 10-Q · filed 2026-08-14 | -$13.47M derived: sum of 2 quarters · filed 2026-08-14 | -$18.25M derived: sum of 3 quarters · filed 2026-08-14 | -$23.08M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2024-09-30 | -$6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$11.59M derived: sum of 2 quarters · filed 2025-12-23 | -$16.42M derived: sum of 3 quarters · filed 2025-12-23 | -$21.15M 10-K · filed 2025-12-23 | ||||
| 2024-06-30 | -$4.77M 10-Q · filed 2025-08-12 | $252.46K 10-Q · filed 2024-08-09 | $742.29K 10-Q · filed 2024-08-09 | -$14.34M 10-Q · filed 2025-08-12 | -$14.18M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$4.84M 10-Q · filed 2025-08-12 | $489.83K 10-Q · filed 2024-05-20 | -$9.56M 10-Q · filed 2025-05-14 | -$9.41M derived: sum of 3 quarters · filed 2025-08-12 | -$8.79M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2023-12-31 | -$4.73M 10-Q · filed 2025-08-12 | -$4.57M derived: sum of 2 quarters · filed 2025-08-12 | -$3.95M derived: sum of 3 quarters · filed 2025-08-12 | $2.42M 10-K · filed 2024-04-16 | ||||
| 2023-09-30 | $157.94K 10-Q · filed 2023-11-20 | $774.24K derived: sum of 2 quarters · filed 2024-08-09 | $1.39M 10-Q · filed 2023-11-20 | -$12.70M 10-K · filed 2024-12-27 | ||||
| 2023-06-30 | $616.30K 10-Q · filed 2024-08-09 | $1.23M 10-Q · filed 2024-08-09 | ||||||
| 2023-03-31 | $611.73K 10-Q · filed 2024-08-09 | |||||||
| 2022-12-31 | $380.81K 10-K · filed 2024-04-16 | |||||||
| 2021-12-31 | -$10.11K 10-K · filed 2023-04-17 | |||||||
| 2021-09-30 | -$10.11K 10-Q · filed 2022-11-28 | |||||||
| 2021-06-30 | -$724.00 10-Q · filed 2022-11-28 | |||||||
| 2021-03-31 | -$9.39K 10-Q · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |